Matthew Tong’s Post

🌟 Exciting collaboration in Wisconsin biotech! Wisconsin-based NorthStar Medical Radioisotopes, LLC will partner with Cellectar Biosciences, Inc. 🌟 This new partnership will integrate NorthStar's Ac-225 into Cellectar's proprietary PLE delivery platform, paving the way for groundbreaking cancer treatments. With promising preclinical results, Cellectar aims to launch clinical trials in 2025 for its radiotherapeutic candidate targeting tough-to-treat cancers like pancreatic and triple-negative breast cancer. 👏 Innovation meets reliability as NorthStar ensures a sustainable Ac-225 supply to fuel the fight against cancer. Read more: https://lnkd.in/gtCkKVJX #Biotech #CancerResearch #WisconsinInnovation

Did you know that fewer than 10% of new cancer drugs make it from the lab to market? The key to overcoming this challenge lies in using the right models for drug development. At MIMETAS, we're redefining cancer drug discovery with our advanced 3D cancer models that accurately replicate human tumor environments. By providing predictive insights, we help bridge the critical gap between preclinical research and clinical success. Discover how our Oncology Services can accelerate your path to breakthrough therapies: https://lnkd.in/gfMUxACw #CancerResearch #CancerTherapies #DrugDiscovery #DrugDevelopment #Oncology

We’re excited to kick off 2025 at 𝐉𝐏 𝐌𝐨𝐫𝐠𝐚𝐧 𝐖𝐞𝐞𝐤 in San Francisco, January 13–16. Our CEO/CFO Peter Llewellyn-Davies and CMSO Dr. Romana Gugenberger will be sharing updates on our innovative oncology pipeline, including developments in #glioblastoma in collaboration with Dana-Farber Cancer Institute:   💊 INV501 – A small molecule that can activate anti-tumor immune responses and has shown promising preclinical results in several solid tumor models. 🧫 INV441 – A TIL-based cell therapy from our proprietary EPiC platform that is advancing towards clinical development in glioblastoma.   🔹 𝐌𝐞𝐞𝐭 𝐮𝐬 𝐭𝐡𝐞𝐫𝐞: Our management team is available for one-on-one meetings at Biotech Showcase and through the BIO partnering platform. Request a meeting via partneringOne or contact us directly at [email protected].   Find out more about our participation and progress in our latest update: https://lnkd.in/dCXuH4xk   #JPMWeek2025 #BiotechShowcase

𝐂𝐥𝐢𝐜𝐤 𝐡𝐞𝐫𝐞 𝐓𝐨 https://lnkd.in/euN7Z8i8 𝐠𝐞𝐭 𝐰𝐞𝐥𝐥-𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 The Mexico Antibody Drug Conjugates (ADC) Market is paving the way for groundbreaking advancements in oncology. Combining the precision of antibodies with the potency of cytotoxic drugs, ADCs are redefining cancer treatment by targeting cancer cells while sparing healthy tissue. With increasing investments in biotech R&D and growing adoption of personalized medicine, Mexico is emerging as a key player in the ADC landscape. 🚀 The future of oncology is here—focused, effective, and life-changing. To Get more:https://lnkd.in/dCyCfKzM #AntibodyDrugConjugates #OncologyInnovation #BiotechMexico #TargetedTherapies #PharmaTrends"

IOS-1002 is a multi-functional agent based on a naturally occurring human leukocyte antigen that targets multiple immune checkpoints ( LILRB1 (ILT2), LILRB2 (ILT4) and KIR3DL1) to activate both innate and adaptive immune cells. IOS-1002 (formerly iosH2) is described as an open format (peptide free conformation) and expression- and stability-optimized HLA-B57-B2m-IgG4_Fc fusion protein.

Designing surface-bioengineered extracellular vesicles to target lung cancer cells: in their latest work, Ireneusz P. Grudzinski and Anna M. Nowicka at University of Warsaw and collaborators bioengineered extracellular vesicles from lung cancer cells, decorating them with the heptapeptide PTHTRWA, the most effective peptide for binding to lung cancer cells. https://lnkd.in/eHukjPtd Preclinical safety assays revealed no cytotoxic or genotoxic effects of these novel bioconstructs, though impedance-based studies indicated some transient impacts on endothelial barrier integrity. An article co-authored by Agata Kowalczyk, Damian Dziubak, Artur Kasprzak, Kamil Sobczak, Monika Rużycka, Magdalena Bamburowicz-Klimkowska, Slawomir Sek, Ivan Rios Mondragon, Teresa Żołek, Elise Rundén Pran, Sergey Shaposhnikov, Mihaela Roxana C. and Maria Dusinska #extracellularvesicles #exosomes #bioengineering #lungcancer #clickchemistry #Vesiculab

🔬 Radiopharmaceuticals Startup Secures $175M Funding for Cancer Treatment 💼 Aktis Oncology raises $175M to advance targeted cancer treatments, focusing on specific tissues. This investment will accelerate their R&D efforts and bring innovative solutions to market. #HealthcareInnovation #CancerResearch #StartupFunding 🟢 This significant funding boost for Aktis Oncology is a positive signal for the healthcare and biotech sectors, highlighting continued investor confidence in innovative cancer treatments. Expect increased market activity and interest in similar startups. https://lnkd.in/dwMYGVq7

🎙️ ASX Briefs Podcast    #Amplia CEO and MD Dr. Chris Burns spoke with ASX Briefs host Andrew Musgrave this week to discuss the Company's progress on the ACCENT trial investigating FAK-inhibitor narmafotinib in pancreatic cancer.     Dr. Burns discussed the growing prevalence of pancreatic cancer globally, and the urgent need for safe and efficacious treatments. He also shared the Company’s latest results from the Phase 2a trial, and the Company’s plans for the year ahead.     "We've just started recruiting our next 24 patients, and we'll finish that recruitment near the end of Q1 2025. At that point, we'll be releasing some early data from that clinical trial, that we think that will be quite interesting. Top line data will come out mid-year, and then a more complete data set by the end of 2025."     Listen here 👉 https://lnkd.in/gGeDHCjQ     $ATX #Amplia #innovation #biotech #pancreaticcancer #clinicaltrial #pharma

💡 Biotech Update! 💡 At the recent ASCO conference, the spotlight was on the potential of Antibody-Drug Conjugates (ADCs) to replace traditional chemotherapy. 🧬✨ These next-gen treatments are designed to deliver targeted therapy with fewer side effects, promising a new era in cancer care. In parallel, AbbVie is making strategic moves to rebuild its portfolio following the Rova-T setback. The focus is now on developing innovative assets that harness the power of ADCs, aiming to revolutionize oncology treatment and improve patient outcomes. Stay tuned as we witness the evolution of cancer therapy and the advancements that could redefine the standard of care. #ASCO #Biotech #CancerResearch #ADCs #Oncology #AbbVie #HealthcareInnovation #NextGenTherapeutics #CancerTreatment 🌐🔬